Gerhardt Attard, MD, PhD, of University College London Cancer Institute, provides insight on the STAMPEDE study which examined the addition of docetaxel to androgen deprivation therapy for patients with metastatic hormone-sensitive prostate cancer.
Results from an ancillary study of the trial were presented at ESMO Congress 2024, in which the Decipher score was used to predict survival benefit of treatment intensification during STAMPEDE.

свернуть